Legal & Regulatory

Traceability

Trade & Brand Protection

Brand & Product Security

Business and Finance

Containers & Shippers

Devices

Software

Cold Chain

Commercial Channels

Artificial Intelligence

Digitalization

Real World Data

Data & Technology

Manufacturing & Packaging

Supply Chain

Logistics & Transportation

Commercialization

Pricing

Trade & Channel

Market Access

Opinion

Adherence

HUB Services

Patient Assistance Programs

Patient Support

News

Pharma Pulse

Academy

Publications

Partner Perspectives

Webcasts

Resources

Conferences

Conference Coverage

Conference Listing

Events

Videos

Peer Exchange

Podcasts

Editorial Podcasts

Subscribe

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

About Us

Advertise

Editorial

Contact Us

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Commerce - Biopharma Business News, Market Insights

Instagram

Facebook

LinkedIn

Threads

Soundcloud

Spotlight

Digital Editions

Security

Asembia AXS25 Summit 

Topics

Data and Technology

Legal and Regulatory

Supply Chain Logistics

1rem

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re exploring new insights into postpartum diabetes risk, a direct-to-consumer initiative from Amgen, and Eli Lilly’s billion-dollar investment in India’s manufacturing infrastructure.

 finds that obesity at age 20 is a strong predictor of postpartum impaired glucose tolerance and diabeteslater in life. Investigators say women who enter pregnancy with higher body weight are more likely to develop metabolic complications, even after delivery. The findings underscore the importance of early intervention and long-term monitoring for women’s metabolic health—particularly during and after pregnancy—to reduce future diabetes risk.

, a new direct-to-consumer digital platform aimed at connecting patients with education, access support, and treatment resources. The initiative reflects a growing trend among pharma companies to meet patients where they are through personalized digital engagement. Amgen says the platform will streamline communication between patients, providers, and pharmacies, helping improve adherence and access to its therapies.

Lastly, in global operations, Eli Lilly is investing 

 to expand manufacturing and supply capabilities in India. The investment will bolster production of active pharmaceutical ingredients and support the company’s growing pipeline of diabetes and obesity therapies. Industry analysts note that this move reinforces Lilly’s strategy to strengthen global supply resilience while positioning India as a key hub in its manufacturing network.

From obesity research and digital patient engagement to global supply chain expansion, these stories highlight how science, strategy, and access continue to evolve across the pharma landscape.

. For more insights on trends transforming pharmaceutical access and care delivery, visit 

Thanks for listening—until next time, stay well and stay informed.

This episode of Pharma Pulse covers new research showing how obesity at age 20 increases postpartum diabetes risk, Amgen’s new direct-to-consumer digital platform aimed at improving treatment access, and Eli Lilly’s $1 billion investment to strengthen manufacturing in India.

Pharma Pulse: Study Links Early Obesity to Postpartum Diabetes Risk, Amgen Launches AmgenNow, and Eli Lilly Strengthens Global Supply Chain

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at the potential impact of a government shutdown on the FDA, updates to Medicare Advantage offerings, and new concerns over US maternal and child health outcomes.

With another federal government shutdown now in effect, analysts 

 that the FDA could face significant operational challenges. Key functions such as drug review timelines, inspections, and post-market safety monitoring may be disrupted if funding lapses. Industry stakeholders say prolonged delays could slow innovation and patient access to critical therapies, underscoring the urgency of stable federal support for regulatory operations.

, with expanded benefits designed to improve affordability and care coordination. The plans include enhanced coverage for preventive services, chronic disease management, and supplemental benefits like dental and vision. Aetna says the offerings aim to meet growing demand among seniors for flexible, comprehensive care solutions.

 published by The Commonwealth Fund finds that maternal and child mortality rates in the US remain higher than in most other high-income countries. Researchers attribute the disparities to gaps in access, inequities in care, and systemic issues within the healthcare system. The findings are prompting renewed calls for targeted policy interventions and expanded maternal health programs to address the crisis.

From the risks of regulatory disruption to changes in Medicare coverage and troubling maternal health statistics, these stories highlight the challenges and opportunities shaping US healthcare in 2026.

This episode of Pharma Pulse covers the potential ramifications of a federal government shutdown on FDA operations, Aetna’s newly announced 2026 Medicare Advantage offerings, and new research showing maternal and child mortality rates in the US remain higher than in most high-income nations.

Pharma Pulse: FDA Faces Shutdown Risks, Aetna Unveils 2026 Medicare Advantage Plans, and US Maternal Mortality Remains High

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at the importance of telehealth during policy uncertainty, the growing popularity of Medicare Advantage special needs plans, and Halozyme’s latest acquisition.

The American Telemedicine Association is 

 that the US must preserve telehealth access to avoid setbacks in healthcare delivery during the federal government shutdown. Advocates argue that telehealth has become an essential lifeline for patients, particularly in rural and underserved communities. Without clear policies, they say millions could face disruptions in care, highlighting the urgent need for permanent telehealth protections.

 from KFF shows that Medicare Advantage special needs plans, or SNPs, are becoming increasingly popular among seniors. Enrollment has more than doubled over the past five years, reflecting demand for tailored coverage options for patients with chronic conditions or complex health needs. Experts note that while SNPs can improve care coordination, they also require careful oversight to ensure quality and equity across different populations.

Lastly, in business news, Halozyme has signed a 

 to acquire Elektrofi, a biotechnology company specializing in ultra-concentrated drug formulations. The deal is expected to expand Halozyme’s drug delivery capabilities and strengthen its partnerships with major pharma companies. Industry analysts say the acquisition could accelerate development of next-generation therapies and broaden Halozyme’s role in biopharma innovation.

From protecting telehealth access and evolving Medicare coverage to major biopharma acquisitions, these stories illustrate the interplay of policy, patient needs, and industry strategy shaping healthcare today.

This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of Medicare Advantage special needs plans, and Halozyme’s $750 million acquisition of Elektrofi to expand its drug delivery portfolio.

Pharma Pulse: Telehealth Access at Risk During Shutdown, Medicare Advantage SNPs Surge, and Halozyme Buys Elektrofi for $750M

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering a new government healthcare initiative, rising prescription trends, and a promising breakthrough in gene therapy.

President Donald Trump has announced plans for a 

 designed to connect patients directly to drug information and pricing resources. The platform aims to improve transparency and give Americans easier access to treatment options. While details remain limited, industry observers say the initiative could reshape how patients engage with pharmaceutical products and pricing in the US.

 show that gabapentin is now the fifth most commonly prescribed medication in US community pharmacies. The drug, often used for neuropathic pain and off-label for anxiety and other conditions, has seen a sharp rise in prescriptions over the past decade. Experts caution that while gabapentin fills critical treatment gaps, its growing use raises questions about appropriate prescribing practices and the potential for misuse.

Lastly, in clinical innovation, researchers have reported that a 

 significantly slows the progression of Huntington’s disease. Early trial results show improvements in motor function and quality of life, offering fresh hope for patients facing this devastating neurodegenerative condition. If future studies confirm these findings, the therapy could become the first disease-modifying option for Huntington’s, a milestone long awaited by patients and caregivers.

From digital health policy and prescribing trends to groundbreaking gene therapy, these stories highlight the rapid changes driving today’s pharmaceutical and healthcare landscape.

This episode of Pharma Pulse covers the Trump administration’s plan to launch a government-run healthcare website for patients, new data showing gabapentin has become the fifth most prescribed drug in community pharmacies, and promising trial results from a novel gene therapy that slows the progression of Huntington’s disease.

Pharma Pulse: Trump Plans Direct-to-Patient Website, Gabapentin Prescriptions Surge, and Gene Therapy Slows Huntington’s Progression

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at concerning measles vaccination trends, a key FDA approval in pediatric dermatology, and AbbVie’s latest investment in US manufacturing.

 show that measles vaccination rates remain well below the herd immunity threshold, raising concerns about the risk of outbreaks. Public health officials warn that coverage gaps are leaving communities vulnerable to a disease that had once been nearly eliminated in the United States. Experts point to misinformation, access challenges, and vaccine fatigue as contributing factors, and are calling for stronger outreach to boost immunization rates.

In regulatory news, the FDA has approved 

 for children ages six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This marks the first approval of an IL-23 inhibitor for pediatric patients in these conditions. Clinical trial results showed significant improvements in skin clearance and symptom control, giving families and providers an important new treatment option.

Lastly, in manufacturing, AbbVie has broken ground on a 

new active pharmaceutical ingredient facility

 in Illinois. The $200 million-plus project is designed to expand domestic production capacity and support AbbVie’s growing pipeline. Company leaders say the site will play a key role in strengthening supply chain resilience and ensuring reliable access to critical therapies.

From lagging measles vaccine coverage to new pediatric treatment approvals and major investments in US manufacturing, these stories underscore the mix of challenges and progress shaping pharma today.

This episode of Pharma Pulse covers new data showing measles vaccine coverage remains below herd immunity thresholds, the FDA’s approval of guselkumab for pediatric plaque psoriasis and psoriatic arthritis, and AbbVie breaking ground on a new API manufacturing site in Illinois.

Pharma Pulse: Measles Vaccination Gaps Persist, FDA Approves Guselkumab for Children, and AbbVie Expands US Manufacturing

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering drug tariff risks, new concerns around pediatric flu, and AbbVie’s latest regulatory filing.

The Trump administration will be imposing a 

 on branded drugs imported into the US, expected to take effect Oct. 1. This has sparked alarm across the pharmaceutical sector, with analysts warning it could drive up costs for patients and disrupt global supply chains.

New research highlights a troubling link between 

pediatric influenza and neurological complications

, including seizures and encephalopathy. The findings have raised concerns about vaccination gaps, as flu shot uptake among children remains below public health targets. Experts stress that improved vaccination coverage is critical to reducing both the direct and long-term impacts of pediatric flu.

Lastly, in regulatory news, AbbVie has submitted a 

 to the FDA for tavapadon, an investigational therapy for Parkinson’s disease. The drug targets dopamine receptors with the aim of improving motor function and potentially reducing side effects associated with current treatments. If approved, tavapadon could represent a meaningful addition to the limited options available for patients managing this chronic, progressive condition.

From drug tariffs and urgent vaccination concerns to advances in Parkinson’s treatment, these stories reflect the intersection of politics, public health, and innovation shaping pharma today.

This episode of Pharma Pulse covers the Trump administration’s 100% tariff on branded drug imports, new research linking pediatric influenza to neurological complications amid vaccination gaps, and AbbVie’s FDA submission for tavapadon, a potential new treatment for Parkinson’s disease.

Pharma Pulse: Drug Tariffs Threaten Access, Pediatric Flu Raises Vaccination Concerns, and AbbVie Files NDA for Tavapadon

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re looking at how Medicaid changes may impact care access, new data on a fixed-dose diabetes therapy, and Bristol Myers Squibb’s latest move in direct-to-patient access.

 shows that childhood insurance dynamics strongly predict how Medicaid cuts will affect access to care. Researchers warn that rollbacks in eligibility and coverage could widen existing gaps, especially for children from low-income families. The findings come as several states reconsider their Medicaid budgets, raising concerns about long-term disparities in pediatric health outcomes.

 has been shown to lower rates of heart failure among patients with type 2 diabetes. By simplifying treatment and improving adherence, the therapy not only enhances glycemic control but also reduces cardiovascular risk. Experts say this could mark a significant step forward in integrated care for diabetes patients, who often face elevated risks of heart-related complications.

Lastly, in other news, Bristol Myers Squibb is expanding direct-to-patient access with a 

 for Sotyktu, its TYK2 inhibitor for moderate-to-severe plaque psoriasis. The initiative aims to make it easier for patients to begin and stay on therapy, part of a broader trend of pharma companies developing patient-centric access models that reduce reliance on traditional pharmacy channels.

From Medicaid policy shifts and new treatment advances to evolving access strategies, these stories reflect the diverse forces shaping healthcare and the pharmaceutical industry today.

This episode of Pharma Pulse covers new research showing Medicaid cuts could widen pediatric coverage gaps, clinical trial data on a fixed-dose combination therapy lowering heart failure risk in type 2 diabetes, and Bristol Myers Squibb’s launch of a direct-to-patient program for Sotyktu to improve psoriasis treatment access.

Pharma Pulse: Medicaid Cuts Threaten Childhood Coverage, Fixed-Dose Combo Reduces Heart Failure in Diabetes, and BMS Expands Sotyktu Access

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering a major shift in US vaccine policy, promising results from a Medicare savings program, and Eli Lilly’s latest manufacturing investment.

The CDC’s vaccine advisory committee has 

 to transition to a broad COVID-19 vaccination recommendation for all adults. This marks a shift away from targeted eligibility criteria, underscoring the agency’s view that COVID-19 vaccination remains a critical tool for long-term public health. Experts say the move should simplify communication and encourage wider uptake, particularly ahead of future seasonal surges.

 shows that the Part D Senior Savings Model has significantly reduced out-of-pocket insulin costs for Medicare beneficiaries, while also improving adherence and diabetes care outcomes. Patients in the program reported paying no more than $35 a month for insulin, leading to better medication consistency and overall health management. Policymakers are watching the model closely as they consider long-term approaches to drug pricing reform.

Lastly, in industry news, Eli Lilly is investing in a 

 in Houston, TX. The site will focus on advanced therapies and support the company’s rapidly growing pipeline, including diabetes and obesity medicines. The expansion highlights Lilly’s ongoing push to strengthen domestic manufacturing capacity and keep pace with rising global demand for its treatments.

From universal vaccine recommendations to reduced insulin costs and major US manufacturing investments, these stories show the dynamic interplay of policy, access, and innovation shaping healthcare today.

This episode of Pharma Pulse covers the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations for all adults, new data showing the Medicare Part D Senior Savings Model lowers insulin costs and improves care, and Eli Lilly’s investment in a new Houston manufacturing facility to support its fast-growing pipeline.

Pharma Pulse: CDC Expands COVID-19 Vaccine Guidance, Medicare Model Cuts Insulin Costs, and Lilly Invests in Houston Facility

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new FDA safety concerns, an sNDA update from GSK, and a major biomanufacturing acquisition.

The FDA has released findings alleging a potential 

association between prenatal acetaminophen use and autism in children

. While the agency stresses that more evidence is needed, the report has already prompted renewed debate among clinicians, researchers, and advocacy groups. Acetaminophen remains one of the most widely used medications during pregnancy, so the FDA is encouraging ongoing studies to clarify risks and guide updated recommendations.

GSK has filed a supplemental new drug application

 to update the label for leucovorin. The proposed update seeks to reflect the medication’s new indication for cerebral folate deficiency. The FDA requested GSK to act on the label change as a part of the agency’s plan to investigate opportunities of repurposing older medications as treatment solutions for chronic diseases, along with the agency’s planned approval for the treatment option.

Celltrion has acquired a major Eli Lilly production plant

 to boost its biologics manufacturing capacity. The facility acquisition strengthens Celltrion’s global supply network and positions the company to better compete in the biosimilars and antibody drug markets. For Lilly, the sale is part of a broader effort to streamline operations and refocus resources on pipeline growth.

From FDA safety reviews to a high-profile manufacturing deal, these stories show how regulation, science, and strategy continue to reshape the pharmaceutical industry.

This episode of Pharma Pulse covers the FDA’s review of a possible link between prenatal acetaminophen use and autism, GSK’s supplemental new drug application to update leucovorin labeling, and Celltrion’s acquisition of an Eli Lilly production facility to expand biologics manufacturing capacity.

Pharma Pulse: FDA Examines Prenatal Acetaminophen Risks, GSK Files sNDA for Leucovorin, and Celltrion Buys Lilly Plant

 podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and today we’re covering new COVID-19 vaccine guidance, Pfizer’s latest acquisition, and a digital innovation aimed at improving GLP-1 adherence.

The CDC’s Advisory Committee on Immunization Practices has shifted its guidance on COVID-19 vaccination for certain groups to a 

. Instead of universal recommendations, providers are encouraged to discuss risks and benefits with individual patients. Experts say this approach reflects the evolving nature of the virus, as well as a growing emphasis on tailoring vaccination strategies to patient needs.

, a biotech focused on obesity and cardiovascular disease treatments. The deal adds promising candidates to Pfizer’s pipeline at a time when competition in the obesity drug market is heating up, particularly around GLP-1 therapies. Analysts see the move as a strategic step to diversify Pfizer’s portfolio beyond COVID-19 products and reinforce its position in high-demand therapeutic areas.

Closed Loop Medicine has teamed up with WeDosify

 to introduce an adaptive dosing platform designed to help patients stick with their GLP-1 treatments. The system personalizes dosing schedules and provides real-time feedback, with the goal of reducing side effects and improving long-term adherence. As GLP-1 demand continues to soar, tools that support patient experience and persistence are becoming a key part of the treatment ecosystem.

From evolving vaccine guidance to pipeline growth and digital adherence tools, these stories highlight the intersection of science, business, and patient care shaping the pharma industry today.

This episode of Pharma Pulse covers ACIP’s move toward shared decision-making for COVID-19 vaccines, Pfizer’s acquisition of Metsera to strengthen its obesity and cardiovascular pipelines, and Closed Loop Medicine’s partnership with Wedosify to improve patient adherence to GLP-1 therapies.

Pharma Pulse: CDC Shifts COVID-19 Vaccine Guidance, Pfizer Buys Metsera for Obesity Pipeline, and New Tech Targets GLP-1 Adherence

Life sciences organizations have an opportunity to move beyond patient-centered care and embrace a model that values lived experience, fosters collaboration, and positions patients as active contributors to research, treatment, and innovation.

Empowering Patients as Partners: The Next Frontier for Pharma Companies

The addition of Evo’s cryogenic shipping and tracking technology enhances Peli BioThermal’s reach across the pharma value chain, driving innovation and integration in temperature-controlled logistics while supporting these therapies.

Peli BioThermal Expands Cold Chain Portfolio With Evo Acquisition to Strengthen CGT Logistics

Amid intensified competition—and evolving IRA and PBM dynamics—leaders in the access space must now adopt a strategist mindset. 

Hubs as Revenue Protection: Rethinking Patient Access in the Era of Disruption 

The new 5-million-cubic-foot biorepository enhances cold chain logistics, expands biopharma storage capacity, and strengthens New Jersey’s position as a life sciences hub.

SciSafe Expands Biopharma Storage With New East Brunswick Facility

Marketed as cost-saving tools, AFPs can also strain safety-net resources.


Alternative Funding Programs Threaten Patient Access

Education Strategies to Counter Misinformation in Obesity Treatments

, Derrick Gastineau, Head of Marketing with Currax Pharmaceuticals, emphasizes the importance of pricing consistency in improving access, affordability, and long-term adherence to obesity treatments, particularly with FDA-approved oral weight loss drugs. He explained that one of the primary frustrations patients face is the unpredictability of out-of-pocket costs. This uncertainty can deter patients from initiating treatment altogether, as they may lack confidence in their ability to sustain the therapy financially over the long term.

Gastineau noted that consistency in pricing addresses this barrier by offering patients a predictable and manageable financial pathway to care. Programs designed to provide reliable cash-pay options, such as those facilitated through mail-order pharmacies, help patients integrate treatment costs into their budgets with greater confidence. This assurance is particularly important in the case of chronic conditions like obesity, where ongoing treatment is essential to achieving meaningful health outcomes.

By stabilizing the cost of therapy, such programs not only improve access but also support adherence. Patients are more likely to stay committed to their medication regimen when they know that affordability will not suddenly become an obstacle. This has significant implications for long-term health benefits, as consistent therapy can lead to better outcomes and reduced overall healthcare costs.

Gastineau highlighted that obesity, like many chronic diseases, requires a long-term treatment approach. Ensuring patients have uninterrupted access to affordable medication is therefore a critical factor in driving sustainable health improvements. In this context, consistent cash-pay programs are not merely financial tools but essential components of chronic disease management.

Ultimately, Gastineau framed the issue as one of equity and sustainability: when patients can rely on steady, affordable access to medications, they are more empowered to take charge of their health and achieve lasting results in managing obesity.

He also described what makes treatment options an attractive alternative from both a clinical and patient experience standpoint; how marketers can effectively communicate the safety and regulatory advantages of approved therapies over compounded or off-label treatments in the weight management space; and what needs to be done to combat bad actors in the sector?

From an education perspective, what needs to be done in order to help combat bad actors in the sector?

I think it starts with having a really firm understanding of where both patients and clinicians are going to get information about medications and different treatment options that are out there.

Then, once we have an understanding of where they're receiving that information, where they're digesting it, making sure that we have a presence there, making sure we're meeting HCPs and patients alike, where they are, trying to make sure that the resources that we're making available—the information and education that we're making available—is really fitting seamlessly into their daily lives. Rather than making them go out and search for it, trying to make sure we're presenting it in a way that fits with their day to day.

In the final part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, shares how the value in ensuring patients and clinicians have access to accurate resources requires meeting them where they already seek information, with seamless, trustworthy education integrated into their daily workflows.

Communicating the Value of Approved Therapies

, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, emphasizes the importance of pricing consistency in improving access, affordability, and long-term adherence to obesity treatments, particularly with FDA-approved oral weight loss drugs. He explained that one of the primary frustrations patients face is the unpredictability of out-of-pocket costs. This uncertainty can deter patients from initiating treatment altogether, as they may lack confidence in their ability to sustain the therapy financially over the long term.

How can marketers effectively communicate the safety and regulatory advantages of approved therapies over compounded or off-label treatments in the weight management space?

There's no doubt that misinformation, just on a broad scale, is as rampant as it has ever been. I think we're seeing that in an even disproportionately high way in the obesity space, due to the attention that is around this disease and these medications right now.

It wouldn't be my place to speculate on the clinical and regulatory aspects comparing approved branded medications and any compounded or off-label prescribing. As a marketer, my main concern is ensuring we're meeting HCPs and patients where they are, and providing them with the information and resources that they need to understand all the relevant aspects of our product and the things that go into their decision-making process: the efficacy and safety profile of the drug, how the drug works, how they can access it, when and how it should be utilized.

Everyone has to make their own decisions about what's best for their health. Everyone has that right, but ensuring they have access to accurate and fairly represented information is the role that we play as pharma marketers.

In the third part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, notes that in a crowded weight management landscape, marketers play a critical role in combating misinformation by ensuring healthcare providers and patients have clear, accurate information on the safety, efficacy, and access pathways of FDA-approved treatments.

Oral Weight Loss Treatments Offer Patients and Clinicians New Options in Obesity Care

With patient fatigue increasing around injectable weight loss therapies, what makes oral treatment options an attractive alternative from both a clinical and patient experience standpoint?

 I'm glad you mentioned both the patient and the clinical side of things, because it's experienced I think on both sides of that treatment conversation that's being had between clinicians and the patients. When we're talking about a chronic health condition with a patient population at the levels of the obesity epidemic that we're experiencing, I think having multiple options in the toolbox for HCPs to choose from, you can't overstate the importance of that when you're managing a very widespread chronic disease, especially one with the heterogeneity of obesity. Likewise, patients need to be informed about all of the available treatment options—emphasis on the word 

—that they have so they can make an educated decision in partnership with their clinician, obviously, about what is best for their health and their individual situation.

Whether it's mode of action, the oral versus injectable medications, mechanism of action, the importance of having different classes of drugs to be able to manage a disease like obesity that is heterogeneous, or even how patients gain access to the medication, we need as many options as possible for this disease, and I'm really happy to see the development that's happening in this space and the innovation that's being brought forward. But there's not only room for, but a need for as many as options as possible to really get a handle around the disease of obesity.

In the second part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, points out that as patient fatigue grows with injectable therapies, oral alternatives are emerging as vital tools for clinicians and patients alike, expanding choice, improving access, and supporting more personalized obesity treatment strategies.

Consistent Cash-Pay Options Could Transform Access to Obesity Medications

How could a consistent cash-pay option for an FDA-approved oral weight loss drug improve access, affordability, and long-term adherence in obesity care?

 Consistency is the key word in that question. We've heard resoundingly from patients that uncertainty around out-of-pocket prices for medications—particularly when we're talking about obesity medications—is one of the biggest frustrations, and sometimes can even be a barrier from a patient even starting a medication if they aren't confident that they're going to be able to afford it and stay on therapy long term. 

By providing programs like this, as well as our Cure Access program that we offer via our mail- order pharmacies that we work with, that provides patients with the reassurance that they're going to have access to the medication at a consistent, affordable price that fits into their life and their individual financial situation, and that's critical when it comes to chronic diseases like obesity, where continuing treatment is critical for the long-term health and outcomes for the patient.

In the first part of his Pharma Commerce video interview, Derrick Gastineau, head of marketing with Currax Pharmaceuticals, explains how predictable, affordable pricing models for FDA-approved oral weight loss drugs can reduce barriers to care, improve long-term adherence, and support better outcomes for patients managing chronic obesity.

How Drug Shortages Could Disrupt Hospital Operations and Strain Patient Care

Drug shortages continue to create significant financial and operational strain on hospitals, impacting both patient care and workforce efficiency. In a video interview with 

In the first part of their Pharma Commerce video interview, Boyede Sobitan and Annika Matas of Zebra Technologies warn that ongoing medication shortages are forcing staff to borrow supplies, delay procedures, and divert nurses from patient care to logistical tasks, creating both financial pressures and operational inefficiencies.

Patient Support

Latest News